Your AI-Trained Oncology Knowledge Connection!

Jason Westin, MD, MS, FACP

home / authors / jason-westin,-md,-ms,-facp

Articles

Ever-Changing Treatment Landscape of Aggressive B-Cell Lymphoma

December 6th 2022

Jason Westin, MD, MS, FACP, discusses recent developments in novel agents to treat and target aggressive lymphomas.

Sitravatinib Plus Tislelizumab Elicits Antitumor Activity in PD-L1+ Advanced NSCLC

Jason Westin, MD, MS, FACP

August 7th 2022

Sitravatinib plus tislelizumab showed a confirmed investigator-assessed overall response rate of 30.4% in PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

Westin Evaluates Management of DLBCL With CAR T-Cell Therapy

Jason Westin, MD, MS, FACP

February 7th 2021

During a Targeted Oncology Case-Based Peer Perspectives virtual event, Jason Westin, MD, MS, evaluated the management of a 63-year-old patient with diffuse large B-cell lymphoma.

Current Treatment Options for DLBCL Besides R-CHOP Chemotherapy

Jason Westin, MD, MS, FACP

March 16th 2020

Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.